CDA Research Group, Inc. Report issue

For profit Phase 2
Founded: Pittsburgh PA United States (2007)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2013
NCT01762670
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

CDA Research Group, Inc.

Active Ingredients

Drugs in Phase 2 Trials (3)

3vm1001 (2 trials)

copper (cu-7) (3 trials)

metronidazole (flagyl) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Chronic Pain (Phase 1)

Neuralgia (Phase 1)

Neuralgia, Postherpetic (Phase 1)

Osteoarthritis (Phase 2)

Osteoarthritis, Knee (Phase 1)

Vaginal Diseases (Phase 2)

Vaginosis, Bacterial (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 3